Arbutus Biopharma Corporation (ABUS)

[Dr_Thorfin]

News out ! ! !

Arbutus today reported the following topline results from the Phase I/II study of TKM-PLK1 in HCC:

TKM-PLK1 was well-tolerated at all dose levels;
51% of subjects showed overall stable disease (SD) according to RECIST criteria;
22% of subjects showed an overall partial response (PR) according to Choi response criteria;
Tumor density reduction of up to 59% was observed;